IMR Press / EJGO / Volume 25 / Issue 2 / pii/2004132

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Editorial Article

Androgens and ovarian cancers

Show Less
1 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei (Taiwan)
2 George Whipple Laboratory for Cancer Research, Department of Pathology and Urology, University of Rochester Medical Center, Rochester, NY (USA)
Eur. J. Gynaecol. Oncol. 2004, 25(2), 157–163;
Published: 10 April 2004

Ovarian cancer is one of the most lethal malignancies in women. Numerous studies indicate that the steroid hormones have been implicated in the etiology and/or progression of epithelial ovarian cancer and support a role for androgens, including: I) androgen receptor (AR) is present in primate ovaries at almost all stages of the menstrual cycle and involve folliculogen­esis and ovulation; 2) high androgen serum levels show high risk of ovarian cancer and ovarian cancer occurring after menopause when the balance of ovarian steroid production shifts from estrogens to androgens; 3) ovarian cancer tissue shows a 90% AR positive rate and is associated with favorable outcomes; 4) androgens promote or inhibit ovarian cancer cell growth; 5) chemotherapy decreases androgen production from cancer cells. This review seeks to summarize our current understanding about the roles of androgens, AR and AR coregulators in the initiation and/or progression of ovarian cancers.

Androgen receptor
Androgen receptor co-regulators
Ovarian cancer
Back to top